Showing 2351-2360 of 7016 results for "".
Clinical Reflections®: Reflecting on Missed Opportunities in Nontuberculous Mycobacteria Lung Disease
https://reachmd.com/programs/cme/clinical-reflections-reflecting-missed-opportunities-nontuberculous-mycobacteria-lung-disease/11059/Explore the recognition and management of nontuberculous mycobacteria lung disease through two engaging patient cases.Clinical and Structural Correlates of COVID-19 Hardship in Latino Adults
https://reachmd.com/programs/clinicians-roundtable/clinical-and-structural-correlates-of-covid-19-hardship-in-latino-adults/36417/New and Emerging PAH Therapies and Approaches: A Mixture of Hope and Complexity
https://reachmd.com/programs/cme/new-and-emerging-pah-therapies-and-approaches-a-mixture-of-hope-and-complexity/36095/There are new and emerging therapies for PAH. Hear our experts discuss treatment approaches and why making the right diagnosis is key for selecting and individualizing therapy.Women’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages
https://reachmd.com/programs/cme/womens-sleep-health-addressing-gaps-in-osa-diagnosis-and-treatment-across-life-stages/36099/Explore women’s life stage–specific factors in OSA diagnosis and management to improve sleep and cardiometabolic outcomes.Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
https://reachmd.com/programs/cme/understanding-igan-fsgs-pathophysiology-and-emerging-therapies/14974/Hear experts discuss how emerging therapies for IgAN and FSGS may achieve proteinuria remission and shape clinical treatment decisions for patients.SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
https://reachmd.com/programs/neurofrontiers/SPOTLIGHT-Registry-Eculizumab-Ravulizumab-gMG/51011/Targeting CD19 in Autoimmune Neuropathy: Case Report Insights
https://reachmd.com/programs/living-rheum/Targeting-CD19-in-Autoimmune-Neuropathy-Case-Report-Insights/32814/Can We Do Better in IgAN?
https://reachmd.com/programs/cme/can-we-do-better-in-igan/14977/What are the limitations of existing therapies in IgAN, and how can emerging therapies complement treatment strategies? Find out from our experts!Adjuvanted vs High-Dose Influenza Vaccines: A Real-World Evidence Study
https://reachmd.com/programs/medical-industry-feature/adjuvanted-vs-high-dose-influenza-vaccines-a-real-world-evidence-study/26668/Explore data comparing adjuvanted and high-dose influenza vaccines for adults 65 and older.Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
https://reachmd.com/programs/cme/chairperson-perspective-acromegaly-care-individualized-diagnosis-and-management-strategies/33027/Join us to discover the current recommendations and scientific data on the diagnosis and therapeutic management of acromegaly.